Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marty Giedlin"'
Publikováno v:
Cell and Gene Therapy Insights. :1539-1549
Autor:
Larry Boyle, Leisa Johnson, Frank McCormick, Annie Shen, John Kunich, Ali Fattaey, Terry Hermiston, Marilyn Lemmon, Marty Giedlin, Kusum Pandey
Publikováno v:
Cancer Cell. 1:325-337
We have engineered a human adenovirus, ONYX-411, that selectively replicates in human tumor cells, but not normal cells, depending upon the status of their retinoblastoma tumor suppressor protein (pRB) pathway. Early and late viral gene expression as
Publikováno v:
Cytotherapy. 19:e17
Autor:
Ishita Siddiq, Dale Ando, Michael G. Fehlings, Marty Giedlin, Eugene Park, Gregory M. T. Hare, Gary Lee, Elaine Liu, Andrew J. Baker, S. Kaye Spratt, Richard T. Surosky
Publikováno v:
Journal of neurotrauma. 29(17)
Vascular endothelial growth factor (VEGF) plays a role in angiogenesis and has been shown to be neuroprotective following central nervous system trauma. In the present study we evaluated the pro-angiogenic and neuroprotective effects of an engineered
Autor:
Meredith L. Leong, Johannes Hampl, Weiqun Liu, Keith S. Bahjat, Eric R. Lutz, Marty Giedlin, Drew M. Pardoll, Dirk G. Brockstedt, Thomas W. Dubensky, Elizabeth M. Jaffee
Publikováno v:
Journal of Immunotherapy. 28:631
Autor:
Charles R. Vitt, Kirk W. Johnson, Mary Beth Giacona, Bob Goodson, Anton F. Ehrhardt, Simon Ng, Jill Winter, John M. Nuss, Ralph Yamamoto, Marty Giedlin, Walter H. Moos, Anke Krebber, Martha B. Ladner
Publikováno v:
Scopus-Elsevier
Peptoids differ from peptides in that peptoids are composed of N-substituted rather than alpha-carbon-substituted glycine units. In this paper we report the in vitro and in vivo antibacterial activities of several antibacterial peptoids discovered by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::210dec18aaf2d9f8b7346b988d896914
http://www.scopus.com/inward/record.url?eid=2-s2.0-0033027897&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0033027897&partnerID=MN8TOARS
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Assess the range of starting T cell percentage in the CTL019 expansion process. The current CTL019 process targets 450e9 total nucleated cells (TNC) at seeding of the static culture bags prior to activation and transduction (Kalos M